GSK Q2 2025 presentation: Sales up 6%, EPS jumps 15% as Specialty Medicines lead growth

GSK plc reported robust Q2 2025 results, with sales up 6% and EPS up 15% at constant exchange rates, primarily propelled by its Specialty Medicines segment, which now constitutes 40% of total sales and grew 13%, driven by strong HIV and oncology performance. The company also improved its core operating margin to 32.9% and increased R&D investment by 11% to advance its pipeline, securing multiple regulatory breakthroughs. GSK confirmed its full-year 2025 guidance and reaffirmed its long-term target of over £40 billion in sales by 2031, signaling continued momentum and strategic execution.

Analysis

GSK plc's Q2 2025 results demonstrate robust operational momentum, with sales growing 6% and core earnings per share increasing 15% at constant exchange rates (CER). The performance underscores a successful strategic pivot, as the Specialty Medicines segment is now the primary growth engine, expanding 13% CER to represent 40% of total sales. This growth is driven by exceptional performance in high-value therapeutic areas, particularly HIV treatments which grew 12%, fueled by long-acting injectables like Cabenuva (+42%) and Apretude (+56%), and significant uptake in oncology with Jemperli sales surging 91%. The company also exhibited strong financial discipline, improving its core operating margin by 180 basis points to 32.9% through SG&A efficiencies and royalty income. Crucially, GSK has translated this strong performance into increased confidence, raising its 2025 growth guidance for the Specialty Medicines segment to low teens percentage growth and reaffirming its long-term outlook for over 7% sales CAGR through 2026 and more than £40 billion in sales by 2031, supported by a pipeline with 15 pivotal readouts expected through 2026.

Key Decisions for Investors

• The strong Q2 earnings beat, driven by high-margin Specialty Medicines and coupled with raised segment guidance, validates GSK's growth strategy and may warrant a bullish stance on the company's fundamentals.
• Investors should monitor the commercial execution and market penetration of key growth assets, particularly long-acting HIV injectables and oncology drug Jemperli, as their continued trajectory is critical for meeting reaffirmed long-term targets.
• With 15 Phase 3 readouts expected through 2026 and a de-risked 2031 sales forecast, portfolios underweight in large-cap pharma with visible growth pipelines should re-evaluate GSK's position, considering these results a significant derisking event.